Windtree Therapeutics Inc

NASDAQ:WINTUnited States

Windtree Therapeutics, Inc. is a biotechnology company. The Company is focused on advancing early and late-stage therapies for critical conditions and diseases. The Company’s portfolio of product candidates includes istaroxime, a Phase II candidate with SERCA2a activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, and preclinical precision aPKCi inhibitors that are being developed for potential in rare and broad oncology applications. Its lead product candidate, istaroxime, is a dual-acting agent being developed to increase blood pressure and improve cardiac function in patients with cardiogenic shock and to improve cardiac function in patients with acute heart failure (AHF) and reverse the hypotension and hypoperfusion associated with heart failure that deteriorates to cardiogenic shock. The Company also has a licensing business model with partnership out-licenses in place.

Contact Information

Headquarters

2600 Kelly Rd Ste 100WARRINGTON, PA, United States 18976-3652

Phone

215-488-9300

Fax

215-488-9301

Executives

Chairman of the Board

Craig Fraser

President, Chief Executive Officer, Director

Jed Latkin

Chief Financial Officer, Senior Vice President, Principal Accounting Officer

Jamie Mcandrew

Chief Operating Officer, Senior Vice President

Eric Curtis

Senior Vice President, General Counsel, Corporate Secretary

Diane Carman